Abstract
Background/aimsTo investigate genotype–phenotype associations in patients withKCNV2retinopathy.MethodsReview of clinical notes, best-corrected visual acuity (BCVA), molecular variants, electroretinography (ERG) and retinal imaging. Subjects were grouped according to the combination ofKCNV2variants—two loss-of-function (TLOF), two missense (TM) or one of each (MLOF)—and parameters were compared.ResultsNinety-two patients were included. The mean age of onset (mean±SD) in TLOF (n=55), TM (n=23) and MLOF (n=14) groups was 3.51±0.58, 4.07±2.76 and 5.54±3.38 years, respectively. The mean LogMAR BCVA (±SD) at baseline in TLOF, TM and MLOF groups was 0.89±0.25, 0.67±0.38 and 0.81±0.35 for right, and 0.88±0.26, 0.69±0.33 and 0.78±0.33 for left eyes, respectively. The difference in BCVA between groups at baseline was significant in right (p=0.03) and left eyes (p=0.035). Mean outer nuclear layer thickness (±SD) at baseline in TLOF, MLOF and TM groups was 37.07±15.20 µm, 40.67±12.53 and 40.38±18.67, respectively, which was not significantly different (p=0.85). The mean ellipsoid zone width (EZW) loss (±SD) was 2051 µm (±1318) for patients in the TLOF, and 1314 µm (±965) for MLOF. Only one patient in the TM group had EZW loss at presentation. There was considerable overlap in ERG findings, although the largest DA 10 ERG b-waves were associated with TLOF and the smallest with TM variants.ConclusionsPatients with missense alterations had better BCVA and greater structural integrity. This is important for patient prognostication and counselling, as well as stratification for future gene therapy trials.
Funder
FFB, USA
Biomedical Research Centre
National Institute for Health and Care Research
UCL Institute of Ophthalmology
Moorfields Eye Hospital NHS Foundation Trust
Santen
Adverum Biotechnologies Inc.
Biogen
FFB
NIH
Research to Prevent Blindness
the Instituto de Salud Carlos III
Ministry of Health, Labour and Welfare of Japan
Foundation Fighting Blindness
The Wellcome Trust
Fight for Sight
Novartis
Malcolm M. Marquis, MD Endowed Fund for Innovation
Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co, Ltd, Acucela Inc, Novartis
Center for Integrative Science
DFG
Spark Therapeutics
German Research Council
Tistou and Charlotte Kerstan Foundation
Foundation Fighting Blindness USA
Spanish Ministry of Health
Excellence Program of the German Government
Acucela Inc.
Active Biotech
Gyroscope Therapeutics Ltd.
Janssen Pharmaceuticals, ProQR Therapeutics
Henry Brent
German Ministry of Education and Research
Janssen Pharmaceuticals
Subject
Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology